CTS™ AIM V™ SFM

Citations et références (31)

Gibco™

CTS™ AIM V™ SFM

Name: CTS™ AIM V™ SFM
SKU: 0870112DK
Price: 309.00 EUR

Le milieu GIBCO CTS AIM V SFM (qualité thérapeutique) est le premier milieu disponible sur le marché sans sérum, définiAfficher plus

Modifier l'affichage

Référence	Quantité
0870112DK	1 000 mL
0870112BK	10 L

2 options

Référence 0870112DK

Prix (EUR)

309,00

Each

Ajouter au panier

Quantité:

1 000 mL

Prix (EUR)

309,00

Each

Ajouter au panier

Le milieu GIBCO CTS AIM V SFM (qualité thérapeutique) est le premier milieu disponible sur le marché sans sérum, défini pour la prolifération et / ou la manipulation des cellules T et des cellules dendritiques et fabriqué conformément aux BPFa. Il contient de la L-glutamine, 50 µg / ml de sulfate de streptomycine et 10 µg / ml de sulfate de gentamicine.

À des fins de recherche ou de fabrication de produits à base de cellules, de gènes ou de tissus. MISE EN GARDE : Non destiné à être directement administré à des humains ou des animaux.

Spécifications

Type de celluleMonocytes, cellules dendritiques, cellules T, hybridomes, PBMC, fibroblastes, macrophages, cellules de myélome, lymphocytes

À utiliser avec (application)Recherche, développement et fabrication de thérapies cellulaires et géniques

FormatFlacon

Qualité de fabricationISO 13485, MDSAP, enregistré auprès de la FDA, 21 CFR 820

Type de produitMilieu pour culture cellulaire

Quantité1 000 mL

Durée de conservation14 mois à compter de la date de fabrication

Conditions d’expéditionTempérature ambiante

ClassificationOrigine animale

FormeLiquide

Serum LevelSans sérum

StérilitéStérilisation par filtration

Unit SizeEach

Contenu et stockage

Stocker le milieu entre 2 et 8°C. Conserver à l’abri de la lumière. AIM V™ a une durée de conservation de 14 mois.

Foire aux questions (FAQ)

What is CTS?

The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

What is the difference between AIM V Medium (Cat. Nos. 12055083, 12055091) and CTS AIM V SFM (Cat. Nos. 0870112DK, 0870112BK)?

The difference is in the intended usage of the two media. AIM V Medium (Cat. Nos. 12055083, 12055091) is for research use only whereas CTS AIM V SFM (Cat. Nos. 0870112DK, 0870112BK) is for research use or manufacturing of cell, gene, or tissue-based products.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

What is the difference between CTS AIM-V Medium and CTS AIM V SFM?

These two media have comparable performance and same cGMP quality. The main difference is that CTS AIM-V Medium (Cat. Nos. A3830801, A3830802, A4672701) does not contain phenol red and antibiotics. This medium formulation has been used as an ancillary reagent in a therapeutic cancer vaccine approved by FDA.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Citations et références (31)

Citations et références

Abstract

Live attenuated lentivirus infection elicits polyfunctional simian immunodeficiency virus Gag-specific CD8+ T cells with reduced apoptotic susceptibility in rhesus macaques that control virus replication after challenge with pathogenic SIVmac239.

Authors:Genescà M, Rourke T, Li J, Bost K, Chohan B, McChesney MB, Miller CJ,

Journal:J Immunol

PubMed ID:17878372

'HIV-specific CD8+ T cells that secrete multiple cytokines in response to Ag stimulation are associated with the control of virus replication during chronic HIV infection. To determine whether the presence of polyfunctional CD8+ T cell responses distinguishes protected and unprotected monkeys in a live attenuated lentivirus model, SIV Gag peptide-specific ... More

Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.

Authors:Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A,

Journal:Cancer Immunol Immunother

PubMed ID:19894047

'The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance, standardization, optimization, and reproducibility. The Assay Working Group of the Cancer Vaccine Consortium (CVC-CRI) has recently identified the choice of serum to be the leading cause ... More

[Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation]

Authors:Nomura K, Fujioka T,

Journal:Nippon Hinyokika Gakkai Zasshi

PubMed ID:8320888

'We evaluated adoptive immunotherapy using LAK cells combined with systemic administration of interleukin-2 (IL-2) in 11 patients with metastatic renal cell carcinoma. The LAK cells were generated by incubation in serum-free medium (AIM-V) supplemented with IL-2 (1,000 U/ml) for 4 days and were generally administered twice weekly (4 times/cycle). Daily ... More

Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection.

Authors:Martinuzzi E, Scotto M, Enée E, Brezar V, Ribeil JA, van Endert P, Mallone R

Journal:J Immunol Methods

PubMed ID:18242633

'The identification of parameters maximizing detection sensitivity in ELISpot assays is important to transfer this technology into the clinical setting for identifying rare Ag-specific CD8(+) T cells. We have therefore considered human IFN-gamma CD8(+) T cell responses against viral epitopes to analyze different variables which could be critical during the ... More

CD4 T cells guarantee optimal competitive fitness of CD8 memory T cells.

Authors:Johansen P, Stamou P, Tascon RE, Lowrie DB, Stockinger B,

Journal:Eur J Immunol

PubMed ID:14971034

We studied the contribution of CD4 T cell help to survival and competitive fitness of CD8 memory T cells specific for influenza virus nucleoprotein. In agreement with recent studies, the optimal generation of functional memory CD8 T cells required CD4 help, although long-term maintenance of resting CD8 memory T cells ... More

View all CTS™ AIM V™ SFM citations